We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Watch Our Video

Read the Latest

October 26, 2020

ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint

Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the ACROBAT Edge and ACROBAT Evolve Studies.

September 21, 2020

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >

Paltusotine (oral SST2 agonist)
Acromegaly
Paltusotine (oral SST2 agonist)
Neuroendocrine Tumors (NETs)
CRN04777 (oral SST5 agonist)
Congenital Hyperinsulinism (congenital HI)
Oral ACTH Antagonist
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
Undisclosed Novel Program
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3

Press Releases

Investor Relations

Investor Relations Crinetics Pharmaceuticals

News